William T. Barry
Oncology · with Barroso-Sousa · 2017
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 34 citations into it
- Immunology — 14 citations into it
Whom William T. Barry trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from William T. Barry's perspective
Ordered by how strongly the researchers William T. Barry trusts endorse each paper. Same corpus, a different order for every researcher.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (Journal of immunotherapy)
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)